Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M35,251Revenue $M1,551Net Margin (%)23.3Z-Score29.7
Enterprise Value $M33,626EPS $1.3Operating Margin %38.7F-Score8
P/E(ttm))74.0Cash Flow Per Share $0.8Pre-tax Margin (%)38.8Higher ROA y-yY
Price/Book11.310-y EBITDA Growth Rate %0Quick Ratio4.8Cash flow > EarningsY
Price/Sales17.35-y EBITDA Growth Rate %52.4Current Ratio5.1Lower Leverage y-yY
Price/Cash Flow115y-y EBITDA Growth Rate %59.3ROA % (ttm)14.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)18.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M198ROI % (ttm)16.0Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNAndreas Halvorsen 2014-09-30 Add0.13%$155.06 - $173.08
($164.22)
$ 177.788%Add 9.59%2,198,451
ALXNRon Baron 2014-09-30 Add$155.06 - $173.08
($164.22)
$ 177.788%Add 27.56%12,941
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 177.788%Reduce -89.45%1,804
ALXNRay Dalio 2014-09-30 Sold Out -0.03%$155.06 - $173.08
($164.22)
$ 177.788%Sold Out0
ALXNAndreas Halvorsen 2014-06-30 Add0.12%$139.61 - $170.2
($157.93)
$ 177.7813%Add 9.23%2,006,092
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 177.7813%Add 240.11%17,094
ALXNRay Dalio 2014-06-30 Reduce-0.03%$139.61 - $170.2
($157.93)
$ 177.7813%Reduce -47.72%26,332
ALXNJohn Burbank 2014-06-30 Sold Out -0.01%$139.61 - $170.2
($157.93)
$ 177.7813%Sold Out0
ALXNRay Dalio 2014-03-31 Buy 0.06%$129.82 - $183.89
($158.27)
$ 177.7812%New holding, 50371 sh.50,371
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 177.7812%New holding, 5026 sh.5,026
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 177.7812%New holding, 10218 sh.10,218
ALXNJohn Burbank 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 177.7812%New holding, 1318 sh.1,318
ALXNFrank Sands 2014-03-31 Reduce-0.74%$129.82 - $183.89
($158.27)
$ 177.7812%Reduce -28.52%5,268,418
ALXNAndreas Halvorsen 2014-03-31 Reduce-0.65%$129.82 - $183.89
($158.27)
$ 177.7812%Reduce -36.16%1,836,658
ALXNAndreas Halvorsen 2013-12-31 Reduce-0.37%$105.48 - $132.91
($119.84)
$ 177.7848%Reduce -16.72%2,877,008
ALXNAndreas Halvorsen 2013-09-30 Reduce-1.06%$94.34 - $117.28
($109.83)
$ 177.7862%Reduce -37.7%3,454,640
ALXNFrank Sands 2013-09-30 Reduce-0.27%$94.34 - $117.28
($109.83)
$ 177.7862%Reduce -10.5%7,540,405
ALXNAndreas Halvorsen 2013-06-30 Reduce-2.15%$87.99 - $107.86
($96.37)
$ 177.7884%Reduce -41.4%5,544,949
ALXNAndreas Halvorsen 2013-03-31 Add2.99%$83.39 - $102.57
($93.13)
$ 177.7891%Add 135.72%9,462,442
ALXNFrank Sands 2013-03-31 Add0.11%$83.39 - $102.57
($93.13)
$ 177.7891%Add 4.23%8,420,336
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ALXN Ron Baron 2014-09-3012,9410.010.01+27.56%
ALXN Andreas Halvorsen 2014-09-302,198,4511.111.5+9.59%
ALXN Frank Sands 2014-09-305,311,4882.682.2+0.6%
ALXN Joel Greenblatt 2014-09-301,80400-89.45%
ALXN Ray Dalio 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sinha VikasEVP & CFO 2014-12-18Sell5,493$182.08-2.36view
BELL LEONARDCEO 2014-12-18Sell30,415$179.73-1.08view
Hallal DavidCOO 2014-12-18Sell5,494$182.03-2.33view
Brennan David RDirector 2014-12-15Buy500$186.99-4.93view
Moriarty John BEVP & General Counsel 2014-12-11Sell3,570$195.53-9.08view
Veneman Ann MDirector 2014-12-11Sell1,235$193.03-7.9view
BELL LEONARDCEO 2014-12-09Sell133,320$198.26-10.33view
Carmichael ClareSVP, Chief HR Officer 2014-12-04Sell10,000$196.25-9.41view
KELLER WILLIAM RDirector 2014-12-04Sell5,000$196.25-9.41view
Sinha VikasEVP & CFO 2014-12-03Sell75,000$198.96-10.65view

Press Releases about ALXN :

Quarterly/Annual Reports about ALXN:

News about ALXN:

Articles On GuruFocus.com
Alexion Pharma Downgraded Despite Progress in Pipeline Jan 05 2015 
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Six High-Impact Sells - Viking Global Investors Aug 26 2013 
CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 


More From Other Websites
Amgen Beats on Q4 Earnings & Revenues, Maintains Outlook - Analyst Blog Jan 28 2015
Up to Speed: Peltz receives ammo in fight against DuPont (Video) Jan 28 2015
Gilead Includes Pan-Genotypic Agent in HCV Licensing Deals - Analyst Blog Jan 27 2015
The Medicines Co. Gets CHMP Recommendation for 3 Drugs - Analyst Blog Jan 27 2015
Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog Jan 27 2015
Apple, Facebook Lead This Week's IBD 50 Earnings Jan 26 2015
Apple, Facebook Lead Top IBD 50 Earnings This Week Jan 24 2015
Minerva Neurosciences Gains on Positive Data on MIN-202 - Analyst Blog Jan 23 2015
Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst Blog Jan 23 2015
BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog Jan 22 2015
Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst Blog Jan 22 2015
Endo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst Blog Jan 22 2015
Keryx to Raise $110 Million Through Issuance of Shares - Analyst Blog Jan 22 2015
Arena Pharmaceuticals to Raise Fund Via Share Issuance - Analyst Blog Jan 22 2015
Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog Jan 22 2015
Celgene to Use Zymeworks' Azymetric Platform for New Drugs - Analyst Blog Jan 22 2015
Kite Pharma (KITE) in Focus: Stock Tumbles 9.2% - Tale of the Tape Jan 22 2015
Keryx Biopharmaceuticals (KERX) in Focus: Stock Falls by 6.8% - Tale of the Tape Jan 22 2015
Alnylam to Raise $450 Million Through Issuance of Shares - Analyst Blog Jan 21 2015
Affymetrix Hits 52-Week High on Strong Top-Line Growth - Analyst Blog Jan 21 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK